Home・Aktien・PerkinElmer Inc

PerkinElmer Inc

Geschlossen

BrancheGesundheitswesen

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 52M
Verkäufe	19M 730M
KGV Branchendurchschnitt	55.248 57.002
EPS	1.41
Dividendenrendite	0.12
Gewinnspanne	7.102
Angestellte	11,000
EBITDA	8.8M 189M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	-0.51% downside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	0.12% 2.22%
Nächstes Ergebnis	26. Okt. 2026
Nächste Dividendenausschüttung	13. Nov. 2026
Nächstes Ex-Dividendendatum	23. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	89M 13B
Vorheriger Eröffnungskurs	0
Vorheriger Schlusskurs	0

Nachrichtenstimmung

By Acuity

20%

80%

32 / 340 Ranking in Healthcare

PerkinElmer Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

PerkinElmer Inc Prognose

Kursziel

By TipRanks

-0.51% Nachteil

12-Monats-Prognose

Durchschnitt 115.14 USD -0.51%

Hoch 130 USD

Tief 105 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für PerkinElmer Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für PerkinElmer Inc – Dist abgegeben haben.

Stimmung

By Acuity

32 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.